Personalis Stock Earnings Reports

Personalis reported strong early-2026 clinical momentum driven by its NeXT Personal MRD test: Q1 clinical volume was >7,800 tests (26% sequential, 258% year-over-year) and more than 1,000 physicians ordered in the quarter. Management reaffirmed full-year revenue guidance of $78M–$80M and expects strategic (clinical + biopharma MRD) revenue to more than double year-over-year to ~$30M–$32M. They reiterated a 2026 biopharma MRD revenue target of $20M–$21M and a clinical volume target of 43,000–45,000 tests for 2026. Key commercial/reimbursement milestones: Medicare coverage in breast (Nov 2025) and lung (Feb 2026) surveillance are already contributing; neoadjuvant breast and a pan-cancer immuno-oncology submission are under MolDX review. Management highlighted strong clinical and real-world evidence (AACR and DARWIN II results), plus a new Variant Tracker product extension. Gross margin compressed to 1.8% in Q1 as the company intentionally prioritizes volume and market share ahead of reimbursement; management expects margins to trough in H1 and improve in H2 with reimbursement uptake, guiding full-year gross margin to 15%–20%. Operating expenses and investments are up (R&D and SG&A) to scale commercial coverage, evidence generation and product innovation, driving a larger net loss (~$105M guide) and expected cash usage of ~ $100M in 2026. Cash and short-term investments were $233.2M at quarter end, with no material debt. Risks/near-term drivers include timing of MolDX/payer decisions, cadence of conversion of unreimbursed volume to reimbursed revenue, and the pace of biopharma trial ramp in H2.